Cargando…

Sex‐specific differences in clot resolution 3 weeks after acute pulmonary embolism managed with anticoagulants—A substudy of the EINSTEIN‐PE study

BACKGROUND: It is unknown whether differences in clot structure and resolution contribute to the reported risk differences of recurrent venous thromboembolism (VTE) between men and women. PATIENTS/METHODS: We used data from the EINSTEIN‐PE study, a randomized, multicenter, non‐inferiority study in w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wiegers, Hanke M. G., van Es, Josien, Pap, Ákos F., Lensing, Anthonie W. A., Middeldorp, Saskia, Scheres, Luuk J. J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	THROMBOSIS
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8360045/ https://www.ncbi.nlm.nih.gov/pubmed/33829647 http://dx.doi.org/10.1111/jth.15326

Ejemplares similares

Heavy menstrual bleeding in women on anticoagulant treatment for venous thromboembolism: Comparison of high‐ and low‐dose rivaroxaban with aspirin
por: Boonyawat, Kochawan, et al.
Publicado: (2021)

Risk of recurrence in women with venous thromboembolism related to estrogen‐containing contraceptives: Systematic review and meta‐analysis
por: Wiegers, Hanke M. G., et al.
Publicado: (2022)

Treatment of Pulmonary Embolism With Rivaroxaban: Outcomes by Simplified Pulmonary Embolism Severity Index Score from a Post Hoc Analysis of the EINSTEIN PE Study
por: Fermann, Gregory J, et al.
Publicado: (2015)

Pulmonary embolism at autopsy in cancer patients
por: Gimbel, Inge A., et al.
Publicado: (2021)

Use of Prestudy Heparin Did Not Influence the Efficacy and Safety of Rivaroxaban in Patients Treated for Symptomatic Venous Thromboem‐bolism in the EINSTEIN DVT and EINSTEIN PE Studies
por: Prandoni, Paolo, et al.
Publicado: (2015)

Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies
por: Wang, Yuqi, et al.
Publicado: (2013)

Clot‐targeted magnetic hyperthermia permeabilizes blood clots to make them more susceptible to thrombolysis
por: Cabrera, David, et al.
Publicado: (2022)

Usefulness of a refined computed tomography imaging method to assess the prevalence of residual pulmonary thrombi in patients 1 year after acute pulmonary embolism: The Nagoya PE study
por: Nakano, Yoshihisa, et al.
Publicado: (2022)

Growth differentiation factor‐15 for prediction of bleeding in cancer patients
por: Mulder, Frits I., et al.
Publicado: (2021)

Citrullinated fibrinogen forms densely packed clots with decreased permeability
por: Varjú, Imre, et al.
Publicado: (2022)

Measurement of coagulation factors during rivaroxaban and apixaban treatment: Results from two crossover trials
por: Scheres, Luuk J. J., et al.
Publicado: (2018)

Efanesoctocog alfa elicits functional clot formation that is indistinguishable to that of recombinant factor VIII
por: Demers, Melanie, et al.
Publicado: (2022)

Effect of gender‐affirming hormone use on coagulation profiles in transmen and transwomen
por: Scheres, Luuk J.J., et al.
Publicado: (2021)

Blocking human protein C anticoagulant activity improves clotting defects of hemophilia mice expressing human protein C
por: Jiang, Miao, et al.
Publicado: (2022)

Anticoagulation in pediatric cancer–associated venous thromboembolism: a subgroup analysis of EINSTEIN-Jr
por: Palumbo, Joseph S., et al.
Publicado: (2022)

Endogenous sex hormones and risk of venous thromboembolism in young women
por: Scheres, Luuk J. J., et al.
Publicado: (2019)

Contemporary best practice in the management of pulmonary embolism during pregnancy
por: Wiegers, Hanke M. G., et al.
Publicado: (2020)

Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism – the J-EINSTEIN DVT and PE program
por: Yamada, Norikazu, et al.
Publicado: (2015)

Outcomes in patients undergoing periprocedural interruption of warfarin or direct oral anticoagulants
por: Lee, Jeffrey, et al.
Publicado: (2022)

Risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer using edoxaban
por: Bosch, Floris T. M., et al.
Publicado: (2021)

Post‐thrombotic syndrome after upper extremity deep vein thrombosis: An international Delphi consensus study
por: de Kleijn, Robert J. C. M. F., et al.
Publicado: (2022)

Effect of anticoagulants on fibrin clot structure: A comparison between vitamin K antagonists and factor Xa inhibitors
por: Gauer, Julia S., et al.
Publicado: (2020)

Defective fibrin deposition and thrombus stability in Bambi (−/−) mice are mediated by elevated anticoagulant function
por: Crawley, James T. B., et al.
Publicado: (2019)

Switching from vitamin K antagonists to direct oral anticoagulants: Treatment satisfaction and patient concerns
por: Toorop, Myrthe M. A., et al.
Publicado: (2020)

Erratum to: ‘Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism – the J-EINSTEIN DVT and PE program’
por: Yamada, Norikazu, et al.
Publicado: (2016)

Heavy menstrual bleeding on direct factor Xa inhibitors: Rationale and design of the MEDEA study
por: Hamulyák, Eva N., et al.
Publicado: (2020)

Quality of life and functional limitations after pulmonary embolism and its prognostic relevance
por: Keller, Karsten, et al.
Publicado: (2019)

Clinical outcome of patients with a vitamin K antagonist‐associated bleeding treated with prothrombin complex concentrate
por: Brekelmans, Marjolein P. A., et al.
Publicado: (2017)

Novel inhibitor ZED3197 as potential drug candidate in anticoagulation targeting coagulation FXIIIa (F13a)
por: Pasternack, Ralf, et al.
Publicado: (2019)

Anti‐β2‐glycoprotein I and anti‐prothrombin antibodies cause lupus anticoagulant through different mechanisms of action
por: Noordermeer, Tessa, et al.
Publicado: (2021)

Impact of different anticoagulation management strategies on outcomes in atrial fibrillation: Dutch and Belgian results from the GARFIELD‐AF registry
por: Seelig, Jaap, et al.
Publicado: (2020)

Extended anticoagulation treatment for cancer‐associated thrombosis—Rates of recurrence and bleeding beyond 6 months: A systematic review
por: Moik, Florian, et al.
Publicado: (2021)

Assessing the clinical probability of pulmonary embolism during pregnancy: The Pregnancy‐Adapted Geneva (PAG) score
por: Robert‐Ebadi, Helia, et al.
Publicado: (2021)

Cleavage of talin by calpain promotes platelet-mediated fibrin clot contraction
por: Fong, Karen P., et al.
Publicado: (2021)

Structure of shear-induced platelet aggregated clot formed in an in vitro arterial thrombosis model
por: Kim, Dongjune A., et al.
Publicado: (2022)

Altered fibrin clot structure and dysregulated fibrinolysis contribute to thrombosis risk in severe COVID-19
por: Wygrecka, Malgorzata, et al.
Publicado: (2022)

Differential sialic acid content in adult and neonatal fibrinogen mediates differences in clot polymerization dynamics
por: Nellenbach, Kimberly, et al.
Publicado: (2021)

Symptomatic subsegmental versus more central pulmonary embolism: Clinical outcomes during anticoagulation
por: Fernández‐Capitán, Carmen, et al.
Publicado: (2020)

Prognostic characteristics and body mass index in patients with pulmonary embolism: does size matter?
por: Beenen, Ludo F.M., et al.
Publicado: (2020)

Prevention of arterial and venous thrombotic events in symptomatic peripheral arterial disease patients after lower extremity revascularization in the VOYAGER PAD trial: Dual anticoagulant/antiplatelet regimen vs antiplatelet therapy alone
por: Berkowitz, Scott D., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8k6h248en8s2nerolhbebkpois